CDTX - Cidara Therapeutics EPS misses by $0.25 misses on revenue
Cidara Therapeutics (CDTX): Q4 GAAP EPS of -$0.49 misses by $0.25.Revenue of $3.73M (+104.9% Y/Y) misses by $6.48M.“We are pleased with our progress across our rezafungin Phase 3 trials and Cloudbreak platforms despite the pandemic-related challenges imposed during the course of 2020. We continue to expect top-line data from the ongoing ReSTORE trial by the end of 2021,” said Jeffrey Stein, Ph.D., President and Chief Executive Officer of Cidara. “In addition, we were thrilled to recently announce the appointment of talented Board members and senior executives to our team, demonstrating the excitement of our early- and late-stage development programs.”Press Release
For further details see:
Cidara Therapeutics EPS misses by $0.25, misses on revenue